The 2026 European Association of Urology (EAU) annual meeting featured an advancements in diagnosis and prognosis, and personalized treatment for renal cell carcinoma (RCC) session and a presentation ...

There has not been a major (or minor) nuclear explosion since the 1960s. This is almost entirely because ...

Radiopharmaceuticals are one of the most exciting frontiers in oncology and targeted therapies today. By combining biologically active molecules with radionuclides, radiopharmaceuticals can deliver ...

There’s a new kid on the block in the fast-growing radiopharmaceuticals category, as Nucleus RadioPharma chalks up an oversubscribed Series A that raised $56 million that will be used to create a ...

Nuclear medicine is entering a new stage of development in Kazakhstan. Modern technologies now make it possible to detect dangerous diseases at an early stage and improve the treatment effectiveness, ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Last month, a team of radiological experts helped secure the safety of Super Bowl LX in Santa Clara, sweeping the area to identify and address any radiological threats.

NEW YORK – Novartis' key patent on its radioligand therapy Lutathera (lutetium Lu 177 dotatate) isn't set to expire until 2038, but radiopharmaceutical company Lantheus is already preparing to ...

The health crisis in Iran and across the Middle East is escalating rapidly, reported Hanan Balkhy, WHO's Regional Director ...

Paul Alcazar (third from left) poses with N3B leadership in front of his award-winning poster at the Waste Management Symposia 2026. From left: Mark Lesinkski, N3B Executive Officer, Sean ...

The speakers emphasize that symptom burden can alter sequencing priorities and prompt greater integration of supportive interventions alongside tumor directed therapy. Regular symptom assessment and ...